NSEAcquisition3d ago · 11 Nov 2026, 05:37 pm
Acquisition
Jeena Sikho Lifecare Limited · JSLL
✦ AI SummaryM&A
Jeena Sikho Lifecare Limited has informed the Exchange about the incorporation of a subsidiary company, Ayugenomics Private Limited, under the provisions of the Companies Act, 2013. The subsidiary will engage in research and development, testing, diagnostics, and clinical services that combine genomics and allied omics sciences with Ayurveda and other AYUSH systems of medicine.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jeena Sikho Lifecare Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Incorporation of Subsidiary Company
Attachments (1)
📄pdf
Download →
JEENASIKHO_11112026173653_Incorporation_Subsidiary_Ayugenomics-_Sign.pdf
View document text
Date: 11th November, 2026
To, To,
Manager - Listing Compliance Head – Listing Operations
National Stock Exchange of India Corporate Relationship
Limited, Exchange Plaza. C-1, Department,
BlockG, BSE Limited
Bandra Kurla Complex, Bandra (E), Phiroze Jeejeebhoy Towers,
Mumbai - 400 051 Dalal Street, Mumbai 400001
SYMBOL: JSLL SCRIP Code: 544476
Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Incorporation of Subsidiary Company.
Dear Sir/Madam,
In continuation of our earlier intimation dated November 04, 2026, and pursuant to Regulation 30 read
with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 (“SEBI Listing Regulations”), we wish to inform you that the Company has successfully
incorporated a subsidiary company under the name “Ayugenomics Private Limited” on 11th
November, 2026 in India, under the provisions of the Companies Act, 2013.
The requisite disclosures in this regard, as prescribed under Regulation 30 of the SEBI Listing
Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated
January 30, 2026, are enclosed herewith as Annexure A.
The aforesaid information will also be made available on the website of the Company at
www.jeenasikho.com.
You are requested to kindly take the above information on record.
Thanking you,
Yours faithfully,
For Jeena Sikho Lifecare Limited
Manish Grover
Managing Director
DIN: 07557886
Place: Zirakpur, Punjab
Date: 11.11.2026
ANNEXURE – A
Disclosure pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.
S. Particulars Details
1. Name of the entity, details in brief such as Name: Ayugenomics Private Limited.
size, turnover, etc.
Date of Incorporation: 11th November, 2026
CIN: U72100DC2026PTC476416
Country of Incorporation: India.
Authorised Share Capital and Paid Up
Share Capital: ₹5,00,000 divided into 50,000
equity shares of ₹10 each.
Turnover: Not applicable, as the company is
newly incorporated and has not commenced
business operations.
2. Whether the acquisition would fall within Ayugenomics Private Limited is a subsidiary of
related party transaction(s) and whether the Jeena Sikho Lifecare Limited and, accordingly,
promoter/promoter group/group companies constitutes a related party of the Company.
have any interest in the entity being
acquired? If yes, nature of interest and Mr. Manish Grover Promoter and Managing
details thereof and whether the same is done Director of Jeena Sikho Lifecare Limited is the
at arm's length. Director of Ayugenomics Private Limited.
The shares of the subsidiary company is
subscribed at “arm’s length” price i.e. face
value.
3. Industry to which the entity being acquired Ayurveda.
belongs.
4. Objects and impact of acquisition (including Objects: To carry on the business of research,
but not limited to, disclosure of reasons for development, testing, diagnostics and clinical
acquisition of target entity, if its business is services that combine genomics and allied
outside the main line of business of the listed omics sciences with Ayurveda and other
entity).
AYUSH systems of medicine. This includes
developing genomics-based panels, tests and
software, clinical decision-support and
artificial intelligence platforms, and clinical
databases and registries.
It also includes conducting clinical studies and
evidence-generation programmes; developing,
validating, manufacturing, licensing and
commercialising evidence-based herbal
nutraceutical and botanical products and
treatment protocols; and offering wellness,
preventive-health, training and certification
programmes. The company will work with
hospitals, government and state programmes
and national and international institutions,
including in Japan and other overseas markets.
It will seek patents, regulatory approvals and
registrations in India and abroad, including
CDSCO and the US FDA, and will own and
commercialise the intellectual property created
by the company.
Impact of acquisition: Ayugenomics Private
Limited has become a subsidiary of Jeena
Sikho Lifecare Limited.
5. Brief details of any governmental or No specific governmental or regulatory
regulatory approvals required for the approvals were identified as presently required
acquisition. for the incorporation, as per the earlier Board-
approved proposal. Any applicable approvals,
registrations or licences required for
undertaking the proposed business activities
shall be obtained from the relevant authorities,
as and when required.
6. Indicative time period for completion of the 11th November, 2026 (Date of Incorporation)
acquisition.
7. Consideration – whether cash consideration Cash consideration through banking channels
or share swap or any other form and details towards subscription to the initial equity share
of the same. capital of the subsidiary.
8. Cost of acquisition and/or the price at which ₹3,00,000, comprising subscription to 30,000
the shares are acquired. equity shares of ₹10 each, as approved by the
Board of Directors.
9. Percentage of shareholding/control acquired The Company shall hold 60% of the equity
and/or number of shares acquired. share capital of Ayugenomics Private Limited,
comprising 30,000 equity shares of ₹10 each.
10. Brief background about the entity acquired Ayugenomics Private Limited is a company
in terms of products/line of business incorporated in India under the provisions of
acquired, date of incorporation, history of the Companies Act, 2013, with its registered
last three years turnover, country in which office in India. The company has been
the acquired entity has presence and any incorporated to undertake research,
other significant information (in brief). development, diagnostics, clinical services and
related activities integrating genomics and
allied omics sciences with Ayurveda and other
AYUSH systems of medicine.
Date of Incorporation: 11th November, 2026
CIN: U72100DC2026PTC476416
History/Turnover: Not applicable, as the
company is newly incorporated and has no
operating history.
Country: India
For Jeena Sikho Lifecare Limited
Manish Grover
Managing Director
DIN: 07557886
Place: Zirakpur, Punjab
Date: 11.11.2026